Introduction
Brain tumour diagnosis made by conventional histological methods depends on the recognition of morphological patterns and the use of a number of special staining techniques. Although the majority of tumours of the central nervous system (CNS) can be diagnosed in this manner, there remains a significant proportion in which the diagnosis is uncertain and other techniques such as electron microscopy are necessary. It follows that the tumours which cause greatest difficulty are those in which the pathologist is denied histological clues. There are three principal situations in which this occurs: (1) when biopsy material is scanty or mechanically deformed; (2) when cells are displaced from their normal anatomical site, as in metastases and cerebrospinal fluid (CSF) infiltrates; (3) when tumours are anaplastic or composed of small round cells. Recognition of cell type by the use of immunological reagents is of the utmost value in all these situations. Brain tumour diagnosis has been enhanced by immunohistological techniques using conventional antisera for at least a decade, with the use of such markers as glial fibrillary acidic protein (GFAP) (Bignami et al. 1972 ). However, this field has recently taken a quantum leap forward with the development of monoclonal antibody technology, allowing the production of unlimited amounts of pure reagent which is ideal for histological work (Kohler & Milstein 1975) .
In this review we describe some of the more recently identified antigenic markers expressed by tumours of the nervous system, and describe the monoclonal antibodies which can recognize them. The use of these antibodies in tumour diagnosis will be discussed.
Tumour antigens defined by monoclonal antibodies Some of the brain tumour antigens defined by monoclonal antibodies have been previously detected by conventional serology, GFAP being a well known example. Other antigens could previously only be recognized by complicated assays involving serum from brain tumour patients and, although biologically interesting, they were impracticable as markers (Coakham 1984) .
The majority of antigens described here are novel and can be assigned to three broad categories: differentiation antigens, epithelial proliferation antigens and oncofetal antigens.
Differentiation antigens: These antigens are present on normal tissue and neoplastic cells derived therefrom, and are extremely useful as markers for tissue-type or germ layer since they are consistently expressed"even in highly anaplastic tumours. Differentiation antigens can be described in terms of their site, being either cytoplasmic or membrane-associated. The former group includes 7-11 nm intermediate filament proteins (IFPs) which form part 'Paper read to Section of Neurology, 12 January 1984. Accepted 15 May 1984 of the cytoskeleton. Five groups of IFPs have been described, four of which are tissue specific and have been comprehensively reviewed by Osborne & Weber (1983) . Table 1 shows these IFP antigens together with examples of monoclonal antibodies used to identify them. It will be seen that vimentin is a less specific marker, since although it is constantly expressed by mesenchymal tumours it is widely distributed amongst other cell types.
The differentiation antigens which are related to the cell surface and are relevant to brain tumour diagnosis are defined by antibodies UJ13A, UJ127.11, 2D1, Bl and UCHTI (Table 2) . Antibody UJ1 3A is a most useful reagent; immunohistologically it will identify all tumours of neuroectodermal origin, both central and peripheral. The single exception is melanoma which does not express this antigen. Its principal role in our laboratories is in the diagnosis of anaplastic or small round-cell tumours in which there is doubt as to the tissue of origin. This antibody has already been used clinically in the removal of neuroblastoma cells from bone marrow prior to autologous transplantation (Treleaven et al. 1984 ) and in radioimmunolocalization of neuroblastoma and brain tumours. Antibody UJ127.11 recognizes an interesting antigen present on all normal neuroectodermal tissue but restricted to tumours of neuronal lineage and also schwannomas. This curious reactivity pattern has yet to be fully explained.
Antibody A2B5 was originally reported as a neuronal marker by Eisenbarth et al. (1979) and was thus included in our panel. However, it was found to stain all neuroectodermal tissues, whether normal or neoplastic, and also stratified squamous epithelium of the foregut and a proportion of metastatic carcinomas (Figure 1 ).
The cell surface differentiation antigen of leukocytes recognized by antibody 2D1 provides a means of rapid identification of lymphoreticular CNS tumours, which can be followed by more detailed typing with the lymphocyte subset markers UCHTI and Bi.
Epithelial proliferation antigens: These antigens, which may be present in small amounts in normal, simple epithelium, are strongly expressed in proliferative states. Antibodies which recognize antigens of this type, HMFG1 and AUA1 (Arklie 1981) , are therefore not specific for neoplasia but are nevertheless of great practical use in identifying carcinoma cells, particularly when used in conjunction with antibodies for cytokeratin (unpublished observation).
Oncofetal antigens: Antigens of this type are restricted to fetal tissue but are re-expressed in adults by tissues that have undergone neoplastic transformation. Whilst these antigens are closer to the ideal of a 'tumour specific' marker, they appear to be expressed more heterogeneously than do the other categories described here. Antibody UJ181.4 recognizes an oncofetal antigen expressed by fetal brain and by the neuroblastic tumours of all types.
It is important to note that many antibodies now exist which recognize the categories of antigens described here, and that the examples given in this review are those with which we *have personal experience.
Many of the antigens useful in tumour diagnosis do not survive the process of formalin fixation and paraffin embedding so that it is becoming increasingly important for frozen tissue to be available. At the same time, strenuous efforts are being made to identify new monoclonal antibodies which react with formalin-fixed, paraffin-embedded material.
Heterogeneous antigenic expression
Malignant tumours are generally composed of heterogeneous cell populations, malignant gliomas being a good example of extreme heterogeneity both morphologically and in vitro (Bigner et al. 1981) . It is therefore not surprising that the expression of certain antigens can vary, either within a given tumour or between tumours of the same histological type. Fortunately, many of the differentiation antigens are persistently expressed, even in the most anaplastic lesions. However, the more 'tumour specific' markers, such as UJ 181.4, are subject to heterogeneous expression. Nevertheless, this can be largely overcome by the use of a panel of antibodies which will greatly minimize the chance of missing a diagnosis. This approach has been successfully employed when examining bone marrow for neuroblastoma cells. A panel of eight monoclonal antibodies were applied to 38 individual bone marrow aspirates heavily infiltrated with neuroblasts. In 21 cases all eight antibodies bound to the sample. The remaining samples were bound by differing numbers of antibodies in the test panel ).
Immunohistological diagnosis
We originally evaluated the diagnostic potential of 50 antibodies when tested on 120 CNS tumours using indirect immunofluorescence and immunoperoxidase techniques in an attempt to select those antibodies which would be most suitable for routine use (Brownell et al. 1982) . As a result of this study it was possible to identify a number of reagents which, when used together as a panel, proved to be highly diagnostic. This panel has now been tested in 164 tumours of the CNS (Coakham et al., in preparation) and has proved to be extremely useful in resolving difficult diagnostic problems.
Certain antibodies serve as individual diagnostic markers for a given tumour type, e.g. 2D1 reliably identifies brain lymphomas, UJ181.4 detects medulloblastomas and LE61 stains the majority of carcinoma metastases. Other antibodies give more general information such as germ-layer origin (UJ13A) or GFAP content (FD19). Figure 1 shows that an individual tumour can be assigned to a diagnostic category based on antigenic profile. This, in itself, is no more accurate than conventional histological evaluation. However, the crucial difference is that the immunological diagnosis is based on molecular (antigenic) identification rather than pure structure so that diagnosis is still possible in instances where morphological clues are missing.
The reactivity pattern of CNS tumours are now briefly described and discussed.
Cerebral gliomas
Gliomas of all types express the pan-neuroectodermal UJ13A antigen, and in our experience all astrocytic gliomas express GFAP in variable amounts, a finding which is consistent with obervations by Velasco et al. (1980) (1980) . Oligoden rogliomas also express antigens related to myelin products, such as myelin-associated glycoprotein, which may prove useful in immunohistological identification (Coakham & Bourne, preliminary observation) .
Medulloblastomas and neuroblastomas
Medulloblastomas can undergo differentiation along both glial and neuronal pathways (Cammins et al. 1980) . The immunostaining patterns with FD 19 and UJ 181.4 reflect this 'mixed' picture in the 10 cases that we have examined and show that certain tumours tend towards either extreme of glial or neuronal expression. Systemic neuroblastomas of childhood express a variety of neuroblastic antigens including those recognized by UJ 181.4 and UJ 127.11. The antigenic profile of these tumours has been described in detail by Malpas et al. (1983) .
The rare cerebral neuroblastomas express the same neuroblastic antigens, lack GFAP, and in tissue culture can express neurofilament ).
Schwannomas
We have recently found that these tumours express the UJ127.11 antigen which was previously thought to be restricted to tumours of neuronal cell type ). This reactivity pattern is interesting in the light of a previous postulate that neuroblastomas might be able to undergo differentiation into Schwann cells (Taxy 1980) . The expression of UJ13A is consistent with the known derivation of Schwann cells from the neural crest.
Meningiomas
The germ layer origin of meningiomas remained controversial for many years before it became accepted that these tumours were neuroectodermal (Rio-Hortega 1962) . This has more recently been supported by serological studies (Winters 1983 ). However, it now seems that these tumours have mixed germ components, since the UJ13A antigen is expressed by the arachnoidal cells and not the fibroblastic component which is likely to be mesenchymal in origin (Garson & Coakham, unpublished observation) .
Metastatic carcinoma
The majority of cerebral and spinal carcinoma deposits can be diagnosed by antibodies recognizing cytokeratin or epithelial proliferation antigens, and if these two reagents are used in combination then the diagnostic efficiency (in 50 cases) is 98%. The only primary intracranial lesions which express cytokeratin are choroid plexus tumours, but these appear to lack epithelial proliferation antigens, so that confusion is unlikely, especially in view of the very different clinical features.
Cerebral carcinoma metastases occasionally express the neuroectodermal UJ13A antigen in addition to cytokeratin (Figure 1 ). We believe that such tumours arise from bronchogenic primary lesions, probably of 'oat cell' type. Small cell carcinomas of lung are known to express neuroectodermal antigens and in our experience these are the only tumours capable of expressing both UJ13A antigen and cytokeratin (unpublished observation).
Primary cerebral lymphoma
This uncommon neoplasm can be accurately diagnosed by monoclonal antibody 2D 1 showing the tumour to be entirely composed of leukocytes. Further characterization is then achieved with the use of lymphocyte subset markers. We have diagnosed 10 such tumours in a two-year period and have shown all to be B-cell non-Hodgkin lymphomas (Allan et al. 1 983b).
Cerebrospinal fluid immunocytology
The application of the above techniques to cytological preparations of CSF in cases of neoplastic meningitis has yielded extremely promising results. Using routine techniques, it can be difficult to identify malignant cells in the CSF and even more difficult to accurately categorize the nature of the malignancy. Initial case reports have demonstrated the value of monoclonal antibodies in diagnosing carcinomatous meningitis when routine techniques proved equivocal (Hancock & Medley 1983 , Coakham et al. 1984b ).
Using an antibody panel, we have extended these observations to neoplastic meningitis of all types including medulloblastoma, neuroblastoma, primitive neuroectodermal tumour, and lymphoma. It was possible to identify malignant cells and accurately categorize the neoplasm in 16 of 17 consecutive cases. Certain of the tumour-cell antigens remain detectable for several days after obtaining the specimen, long after cytological appearances have deteriorated. This is of practical importance since one of the difficulties which the cytologist encounters is the early deterioration of morphology (Coakham et al. 1984a ).
Conclusion
The range of monoclonal antibodies currently available permits the assembly of panels of reagents which can accurately categorize malignant cells in tissue sections or cytological preparations. This is a powerful technique which has already been of proven value in general histological and cytological practice (Gatter et al. 1982 , Ghosh et al. 1983 ).
Using immunofluorescence, results can be obtained relatively rapidly when necessary (within one hour of receiving the specimen) and this proves a considerable advantage over other diagnostic techniques such as electron microscopy.
The systematic application of an antibody panel in CNS tumour diagnosis suggests that 20% of cases are likely to benefit from such techniques and that this approach is of most value in the differential diagnosis of small round-cell tumours, more specifically (1) in classifying the neuroblastic and primitive tumours of childhood; (2) in the differential diagnosis of secondary carcinoma from lymphoma; and (3) in categorizing brain lymphomas (Table 3) . Just as it is possible to classify lymphomas and leukaemias according to their stem cell of origin, it may soon be possible to achieve a more biological classification of primary cerebral tumours by identifying antigenic phenotypes which relate to neuroectodermal stem cell origin. The prophetic nature and significance of the histogenetic classification of brain tumours, originally proposed almost 60 years ago by Bailey & Cushing (1926) , may then be fully appreciated.
